Capsida Announces AbbVie Opt-in for First Genetic Medicine …
4 days ago · Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties. THOUSAND OAKS, Calif., January 7, 2025 – Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $40 million license payment and is eligible for ...
Capsida Announces AbbVie Opt-in for First Genetic Medicine …
3 days ago · THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative disease program under ...
AbbVie exercises $40M option for Capsida-partnered gene therapy
3 days ago · Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.
News - Capsida Biotherapeutics
AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify ...
AbbVie and Capsida Biotherapeutics Expand Strategic ... - News
Feb 23, 2023 · AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.
AbbVie and Capsida Biotherapeutics Expand Strategic …
Feb 23, 2023 · AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.
AbbVie and Capsida Biotherapeutics Expand Strategic …
Feb 23, 2023 · AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs....
AbbVie and Capsida Strike $674 Million Gene Therapy
Feb 24, 2023 · AbbVie and Capsida Biotherapeutics, a biopharma company specializing in next-generation gene therapy platforms, announced an expanded strategic collaboration on Feb. 23, 2023.
AbbVie and Capsida Strike $674 Million Gene Therapy …
Feb 24, 2023 · AbbVie and Capsida Biotherapeutics, a biopharma company specializing in next-generation gene therapy platforms, announced an expanded strategic collaboration on Feb. 23, 2023.
AbbVie and Capsida partner for eye disease gene therapies
Feb 24, 2023 · AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics for the development of targeted genetic medicines to treat eye diseases with high unmet needs. The latest partnership builds on the 2021 neurodegenerative disease collaboration.
- Some results have been removed